Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation

Immunobiology

Volumn 204, Issue 4, 2001, Pages 434-441

  Tian, Haijun ^a,b   Xiao, Yi ^a,b   Qin, Li ^a,b   Chen, Ying Hua ^a,b  

^a Centers for Preventive Medical Research   (China)

^b TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIBODY; CARRIER PROTEIN; EPITOPE; GLYCOPROTEIN GP 120; KEYHOLE LIMPET HEMOCYANIN; MUTANT PROTEIN; PEPTIDE; VACCINE; VIRUS ENVELOPE PROTEIN;

ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTIGENICITY; ARTICLE; ASSAY; CONJUGATION; DRUG DESIGN; EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOBLOTTING; MUTATION; PRIORITY JOURNAL; SYNTHESIS; VIRUS MUTATION;

EID: 0035214751     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1078/0171-2985-00053     Document Type: Article

References (25)

1. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma
2. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
3. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
4. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
5. HIV type 1 coreceptors, neutralization serotypes, and vaccine development
6. Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines
7. HIV-1 neutralizing antibodies: How full is the bottle?
8. HIV vaccines - Magic of the occult?
9. Epitope-vaccine: A new strategy against HIV-1
10. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant
11. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein
12. Structure and polymorphism of HIV-1 third variable loops
13. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
14. Local and global structural properties of the HIV MN V3 loop
15. Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics and neutralization
16. V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity
17. Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity
18. Isolation and characterization of human immunodeficiency virus type 1 variants infectious to brain-derived cells: Detection of common point mutations in the V3 region of the env gene of the variants
19. A strategy for rational design of fully synthetic glycopeptide conjugate vaccines
20. Induction of high levels of epitopespecific antibodies by epiope/peptide candidate vaccines against human immunodeficiency virus type 1 (HIV-1)
21. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein
22. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5
23. Genetic variations and molecular epidemiology of the Ruili HIV-1 strains of Yunnan in 1995
24. Region of gp120 genes among HIV-1 strains in Guangxi autonomous region of the Zhuangs
25. Production of resistant HIV mutants during antiretroviral therapy